BioXcel Therapeutics Inc
Veridion Score
Composite trend over time
Why is BTAI moving today?
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for BTAI.
BTAI insider activity
BioXcel Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$43K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | 2026-05-20 | Yocca Frank | Insider | sell | $1.08 | 6,845 | 26,175 | $7K | SEC Form 4 |
| 2026-05-22 | 2026-05-20 | Rodriguez Javier | Insider | sell | $1.08 | 6,560 | 26,803 | $7K | SEC Form 4 |
| 2026-05-22 | 2026-05-20 | Mehta Vimal | Insider | sell | $1.09 | 19,419 | 69,598 | $21K | SEC Form 4 |
| 2026-05-22 | 2026-05-20 | Steinhart Richard I | Insider | sell | $1.08 | 6,845 | 26,300 | $7K | SEC Form 4 |
BTAI contract awards, year to date.
Public federal awards linked to this ticker.
BTAI lobbying filings, year to date.
Registered lobbying filings matched to BioXcel Therapeutics Inc.